On February 13, 2023, the Board of Directors of Vir Biotechnology, Inc. appointed Sung Lee as Executive Vice President and Chief Financial Officer of the Company, effective as of March 27, 2023. Howard Horn will step down as Chief Financial Officer of the Company effective upon Mr. Lee's appointment on the Effective Date, and will remain with Vir as Executive Vice President until April 28, 2023, to assist with the transition. Mr. Lee, 52, has served as the Chief Financial Officer and Management Board member of MorphoSys AG, a biopharmaceutical company, since February 2021.

Previously, from October 2019 through February 2021, he served as the Executive Vice President and Chief Financial Officer of Sangamo Therapeutics, Inc., a biotechnology company. Prior to that, Mr. Lee served in various roles at Gilead Sciences, Inc., a biopharmaceutical company, from 2005 through October 2019, most recently as Senior Vice President, Financial Planning & Analysis and Investor Relations from March 2019 to October 2019. Previously, Mr. Lee served as Vice President of Financial Planning & Analysis and Investor Relations from September 2018 to February 2019, Vice President of Investor Relations from June 2016 to August 2018 and Senior Director, Investor Relations from 2013 to May 2016.

From 2010 to 2013, Mr. Lee was the Head of Europe Financial Planning & Analysis and prior to that served as the Head of Research & Development Financial Planning & Analysis from 2006 through 2010. Mr. Lee received a B.A. from the University of California, Irvine and an M.B.T. from the University of Southern California.